Press release
Oramed Granted Key European Patent for Platform Technology in Oral Delivery of Proteins
- Protease inhibitor is a key component of Oramed's PODTM technology that protects therapeutic proteins in the digestive system - Oramed has already been
About this update from Oramed Pharmaceuticals Inc.
[{"type":"text","content":"- Protease inhibitor is a key component of Oramed's PODTM technology that protects therapeutic proteins in the digestive system\n - Oramed has already been granted this patent in the United States and Japan\n\n\nNEW YORK, Jan. 5, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the European Patent Office has granted the Company a patent titled \"Protease Inhibitor-Containing Compositions, Compositions Comprising Same, and Methods for Producing and Using Same.\" The patent supports Oramed's oral protein delivery platform technology which underlies its lead drug candidate ORMD-0801 now in pivotal Phase 3 studies and positioned to potentially be the first oral insulin capsule on the market. The granted patent covers a unique method for the purification of raw protease-inhibiting materials which are a key component of the platform technology that protects therapeutic proteins in the digestive system. \n\"With this newly granted patent, we now have 88 patents granted and 35 more pending, further fortifying Oramed's leading position with respect to intellectual property assets addressing the oral delivery of therapeutic proteins currently only available via injection,\" stated Oramed CEO Nadav Kidron. \nAbout Oramed Pharmaceuticals\nOramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901). \nFor more information, please visit www.oramed.com.\nForward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss the expected timing of topline results of our Phase 3 studies or the potential of ORMD-0801 to be...